SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid reports that the US president is considering reclassifying marijuana, which has sparked significant community discussion around potential benefits like tax relief and increased investment.  Traders are actively debating the likelihood and impact of the potential policy change, with some anticipating a major short squeeze while others express skepticism. Overall, the news has injected volatility and renewed interest in cannabis stocks.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending down despite positive earnings, as investors express concern regarding AI margin fears, customer concentration, and guidance. Community discussions revolve around whether the dip is an overreaction and a buying opportunity, or the start of a larger correction in the AI sector. Some traders speculate about potential for a dead cat bounce or further downside depending on market sentiment.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is trending as analysts updated their target price forecasts, sparking renewed community discussion. Community members are also discussing the company's potential to benefit from shifts in immigration policy and contract wins, while others debate the ethical implications of investing in private prisons. The stock's movement appears tied to broader political and policy cycles related to immigration and detention.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation around potential cannabis rescheduling and executive action, driving optimism in the sector. The community is focused on potential catalysts like Trump's actions and Supreme Court decisions that could lead to significant re-rating and M&A activity. Discussions also center on identifying undervalued plays within the cannabis space, particularly those poised for substantial growth if regulatory changes materialize.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as traders discuss its low float, potential short squeeze, and possible breakout, drawing comparisons to other HK stocks like $SMX and $OCG. Community members are closely watching for a golden cross setup and anticipate upward momentum if the stock moves above the $6 and $8 levels. The stock is known for crazy moves and potential for an after-hours run.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as investors debate its future, with some citing improving free cash flow and AI potential as reasons to buy, while others express concerns about leadership and profitability. Discussions also center around a potential buyout and the upcoming specs release. Sentiment appears mixed as the stock experiences volatility amid broader market fluctuations.

Argo Blockchain Plc operates as a blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. It mines using purpose-built computers to solve cryptographic algorithms in the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Argo Blockchain Plc - ADR

Argo Blockchain Plc

Argo Blockchain is trending due to discussions around its reverse stock split and London Stock Exchange delisting, with the community debating potential impacts. Some traders anticipate a rebound and short squeeze given the low float post-split, while others express skepticism about the company's financial health and potential for further dilution. Overall, the conversation reflects a mix of speculative hope and concern amidst restructuring efforts.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its position as the top meme coin on the Bitcoin network, emphasizing its unique attributes like a fair airdrop and fully open-source nature. Talk centers on its strong community, treasury growth, and potential listings, reinforcing bullish sentiment amidst market volatility. As a Bitcoin-native meme, it contrasts with other meme coins, emphasizing its permanence and cultural relevance within the crypto space.

RYTHM, Inc. engages in the development of hardware and software solutions for indoor agriculture. The company was founded on June 6, 2016 and is headquartered in Rolling Meadows, IL.

RYTHM Inc.

RYM is experiencing a surge in interest, with community members pointing to it as a potential runner and top gainer alongside other volatile stocks. Discussions revolve around potential after-hours pumps and comparisons to previous high-flying tickers, with some traders highlighting the stock's low float as a catalyst for significant price movement.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending alongside other cannabis stocks amid speculation that the U.S. federal government might ease marijuana restrictions, with community members actively discussing the potential impacts of policy changes. Chatter revolves around an executive order from President Trump to reclassify cannabis, although some traders are wary of potential 'pump and dump' scenarios. Investors are weighing the implications for legacy cannabis companies like ACB given the broader sector's volatile history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share.</li><li>The split will reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million</li><li>Total authorized share count will remain unchanged at 500 million.</li></ul>&nbsp;Shares of Moleculin Biotech Inc. (MBRX) plunged over 25% on Wednesday to their lowest in five months, after the company announced a reverse stock split.Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective Dec. 1, 2025, following which, the company’s shares will begin trading on a post-split basis on the Nasdaq Capital Market under the existing ticker symbol MBRX.<h2 class="st-heading-2">The Reverse Split</h2>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share. Moleculin added that it will not issue fractional shares, and any shareholder entitled to one will receive a cash payment to replace the fractional amount.The move will significantly reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million, while the total authorized share count will remain unchanged at 500 million.Companies often use reverse splits to avoid being delisted, as primary exchanges require stocks to maintain a minimum price of $1.00. If a stock trades below this level for 30 straight sessions, the company receives a deficiency notice and is given a limited window to lift the share price. A reverse stock split can help the firm regain compliance and keep its listing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MBRX">MBRX</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.&nbsp;&nbsp;One user believes a share repurchase could go some way in boosting confidence.<stembedurl>https://stocktwits.com/Healthpro/message/637501819</stembedurl>MBRX stock has fallen more than 80% so far this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-de-stock-falling-today/cL538QhREWX">Why Is DE Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did MBRX Stock Plummet Over 25% Today?

Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective December 1.

Equity

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved its Clinical Trial Application for a pivotal Phase 2B/3 study of Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia.The European Medicines Agency approved the randomized, placebo-controlled trial in all nine European Union countries where Moleculin Biotech filed it.&nbsp;It will include research locations in the U.S. and the Middle East.&nbsp;Moleculin Biotech shares closed 2.86% higher at $1.08 on Monday, before slipping 3.7% to $1.04 in after-hours trading.Researchers will combine the Phase 2B study with Phase 3 testing to measure primary efficacy according to international regulatory requirements.Part A of the trial will recruit between 75 and 90 patients randomly assigned to receive HiDAC with a placebo or one of two FDA-approved Annamycin doses of 190 mg/m² or 230 mg/m².&nbsp;The initial patient data set from 45 participants will become available during the second semester of 2025, and researchers anticipate the second unblinding to occur at the beginning of 2026.&nbsp;The trial will expand to include approximately 220 patients during Phase 3 enrollment (Part B).EMA approval depends on Moleculin providing nonclinical GLP data before starting Part B, necessitating protocol modifications afterward.&nbsp;The trial uses an adaptive design that supports the FDA’s Project Optimus goal of improved oncology dose selection.The company remains on course to deliver its expected interim readout this year, as patient dosing has already started.On Stocktwits, retail sentiment was ‘bullish’ amid a 3,700% surge in 24-hour message volume.Some traders expressed appreciation for the stock’s steady performance, with one noting that market makers were doing a good job “keeping it tight” for those accumulating shares of Moleculin.<stembedurl>https://stocktwits.com/CrisMars/message/614378232</stembedurl>Another described the 2.86% rise of the stock as “decent” and said “low and slow will win the race.”<stembedurl>https://stocktwits.com/BiggPapa/message/614389064</stembedurl>The stock has declined nearly 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup 

The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

These five biotech stocks, all belonging to nano-, small- or mid-cap categories, notched the highest jump in Stocktwits message volume in the week ended Feb. 14, 2025:GlycoMimetics Inc. (+550% jump in chatter)GlycoMimetics, a late-stage biotech firm developing glycobiology-based cancer therapies, saw a surge in retail interest after a minor amendment to its merger agreement with Crescent Biopharma. The update refined the financing structure but kept intact the exchange ratio and ownership split. Once the deal closes, Crescent security holders, including new investors, will own about 96.9% of the combined company. Shares are up roughly 16% year-to-date (YTD).GRAIL Inc. (+500% jump in chatter)Cancer detection firm GRAIL made waves after announcing a partnership with Quest Diagnostics (DGX) to distribute its Galleri multi-cancer early detection test. Analysts at Guggenheim viewed the move as a major step toward broader accessibility. The stock has soared over 208% YTD.ADMA Biologics Inc. (+400% jump in chatter)ADMA Biologics, a biopharma company focused on plasma-derived therapies, saw rising buzz ahead of its upcoming fourth-quarter (Q4) earnings. Last month, it issued a preliminary report projecting full-year 2024 revenue between $417 million and $425 million, with total cash holdings exceeding $100 million. Despite the strong forecast, shares remain down more than 8% YTD.Moleculin Biotech Inc. (+295% jump in chatter)Moleculin Biotech gained traction after the FDA provided guidance on its Phase 3 trial for Annamycin, a next-generation anthracycline designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. With an adjusted trial size, the company expects its first unblinding in late 2025 and another in early 2026. Shares have climbed over 25% YTD.Exelixis Inc. (+200% jump in chatter)Exelixis, an oncology-focused biotech, saw a surge in discussions after reporting Q4 earnings that topped estimates, prompting analysts to raise their price targets. Citi highlighted continued strength in its Cabometyx franchise and pointed to Zanza as a potential blockbuster drug. Shares are up 4.35% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

This account has been verified as an official MBRX representative.

Verified Account

Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

MBRX
Moleculin Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MBRX News

MBRXMoleculin Biotech Inc